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 3 
Running title: Fitness of rpoB variants in HIV coinfected TB patients 58 
 59 
Abstract 60 
We analysed 312 drug-resistant genomes of Mycobacterium tuberculosis (Mtb) collected from HIV 61 
coinfected and HIV negative TB patients from nine countries with a high tuberculosis burden. We 62 
found that rifampicin-resistant Mtb strains isolated from HIV coinfected patients carried 63 
disproportionally more resistance-conferring mutations in rpoB that are associated with a low fitness 64 
in the absence of the drug, suggesting these low fitness rpoB variants can thrive in the context of 65 
reduced host immunity.  66 
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 4 
Tuberculosis (TB), caused by members of the Mycobacterium tuberculosis (Mtb) Complex, is a 85 
leading cause of death worldwide, killing more people than any other infectious disease. Among the 86 
many factors driving the global TB epidemics, two factors stand out as particularly important: 87 
antibiotic resistance and HIV coinfection (1). Although the impact of both of these factors 88 
individually is well recognized, the interaction between them is less clear and likely depends on the 89 
particular epidemiologic setting (2). HIV coinfection and drug-resistant TB often coexist in severe 90 
epidemics, which could indicate spread of drug-resistant Mtb strains from immune-compromised 91 
patients (3–5). The propensity of drug-resistant Mtb strains to spread is influenced by the fitness cost 92 
associated with drug resistance determinants (6). Specifically, bacterial strains that have acquired drug 93 
resistance-conferring mutations may be less transmissible than their susceptible counterparts, 94 
although this fitness cost can be ameliorated by compensatory mutations (7–10). Moreover, the effect 95 
of different resistance-conferring mutations on fitness can be heterogeneous (11).  In the clinical 96 
setting, there is a selection for high-fitness and/or compensated drug-resistant Mtb strains in TB 97 
patients (12). However, in immune-compromised hosts, such as HIV coinfected patients, even strains 98 
with low-fitness resistance mutations might propagate efficiently (13–15), which could partially 99 
explain why drug-resistant TB has been associated with HIV co-infection (16, 17). However, to date, 100 
no evidence directly supports the notion that the immunological environment created by HIV co-101 
infection modifies the fitness of drug-resistant Mtb (5, 18, 19).  102 
In this study, we tested the hypothesis that resistance-conferring mutations with low fitness in Mtb are 103 
overrepresented among HIV-coinfected TB patients. We focused our analysis on isoniazid and 104 
rifampicin, the two most important first-line anti-TB drugs, for which resistance-conferring mutations 105 
have been shown to differ in their fitness effects when measured in the laboratory (11). In addition, 106 
the frequency of the resistance alleles found in a clinical setting correlates well with the in vitro 107 
fitness of strains (20, 21). To explore the association between HIV coinfection and the fitness effect of 108 
different drug resistance-conferring mutations in Mtb, we compiled a collection of drug-resistant 109 
strains using the global International epidemiology Databases to Evaluate AIDS (IeDEA, 110 
http://www.iedea.org) consortium (22, 23) as a platform. For this study, 312 strains were collected 111 
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 5 
from HIV-coinfected and HIV uninfected TB patients originating from nine countries on three 112 
continents: Peru, Thailand, South Africa, Kenya, Côte d’Ivoire, Botswana, Democratic Republic of 113 
the Congo, Nigeria and Tanzania (supplemental methods, Figure 1 and supplemental Table S1). The 114 
association between the fitness of isoniazid resistance-conferring mutations and HIV coinfection was 115 
tested in a univariate analysis (Figure S1). Isoniazid resistance-conferring mutations were divided into 116 
three groups, as previously described (24): katG S315T mutation, katG mutations other than S315T, 117 
and inhA promoter mutations only. The S315T substitution in katG causes high-level isoniazid 118 
resistance, while retaining some catalase/peroxidase functions (25). Conversely, the inhA promoter 119 
mutation does not affect KatG activity. Other substitutions/deletions in katG have been associated 120 
with a lower fitness in the laboratory and are observed only rarely among clinical isolates (24, 26, 27). 121 
In the case of rifampicin, the association between the fitness of rpoB variants and HIV coinfection 122 
was tested in both a univariate and multivariate analysis (Table 1). Resistance-conferring variants in 123 
rpoB were classified into two groups based on their fitness effects documented previously (11, 28, 124 
29). The mutation rpoB S450L was considered ‘high-fitness’, since this mutation was previously 125 
shown to confer a low fitness cost in the laboratory (11) and is generally the most common in clinical 126 
strains (30). Any other resistance-conferring mutation affecting rpoB was considered ‘low-fitness’ 127 
(11). The multivariable logistic regression model with outcome “low fitness rpoB variants” was 128 
adjusted for host-related factors (history of TB, country of isolation, sex and age) (31) and bacterial 129 
factors (Mtb lineage, presence of a rpoA/C compensatory mutation, clustering of the genome inferred 130 
by genetic relatedness). Seventy-six patients from Tanzania and Botswana were excluded from the 131 
model due to missing or unknown clinical data. 132 
Out of 312 patients, 113 (36.2%) were HIV-coinfected, 120 (38.5%) were women, 115 (37%) were 133 
newly diagnosed TB cases (therefore treatment naïve), 276 (88.5%) harboured isoniazid resistance-134 
conferring mutations, with or without additional resistance, and 282 (90.4%) harboured rifampicin 135 
resistance-conferring mutations, with or without additional resistance. In total, 78.8% (n= 246) of the 136 
strains were classified as being at least MDR, defined as resistance to isoniazid and rifampicin with or 137 
without additional resistance to 2nd line drugs. Amongst the 113 HIV coinfected individuals, 34 (30%) 138 
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 6 
were on antiretroviral therapy (ART), 26 (23%) were not, and 53 (47%) had unknown ART start date. 139 
Four of the seven known Mtb lineages were represented in the following proportions: 11 L1 (3.5%), 140 
57 L2 (18.3%), 38 L3 (12.2%), 206 L4 (66.0%). After dividing a total of 276 isoniazid-resistant 141 
strains into the three groups of isoniazid resistance-conferring mutations defined above, we found 142 
similar proportions in HIV-coinfected and HIV-uninfected patients (chi-square test, p=0.54, Figure 143 
S1), and as expected, the katG S315T mutation was the most frequent mutation in both categories 144 
(overall, found in 80% of isoniazid-resistant strains). In the case of rifampicin resistance, a univariate 145 
and multivariate analysis of 203 strains with complete clinical records, indicated that HIV coinfected 146 
TB patients carried a higher proportion of low-fitness rpoB resistance variants in comparison to HIV 147 
negative patients (72.3% vs. 51.4%). The univariate analysis showed higher odds of having a low-148 
fitness rpoB variant in HIV coinfected patients (Odds Ratio 2.46 [95% Confidence Interval 1.30-149 
4.66], p=0.006, Table 1). Our multivariable regression analysis confirmed these results and showed an 150 
association between low-fitness rpoB variants and HIV-coinfection, whilst controlling for other 151 
factors (Odds Ratio 4.58 [95% Confidence Interval 1.69, 12.44], p=0.003, Table 1). This association 152 
can be explained at least in two ways. Firstly, HIV-coinfected patients are thought to have fewer lung 153 
cavities on average and lower sputum bacillary load (32, 33). The resulting smaller Mtb population 154 
size would lead to fewer replication events, possibly reducing the number of mutations available for 155 
selection to act upon. In other words, low-fitness variants and high-fitness variants would co-occur 156 
less often in an HIV-coinfected patient, such that competition between them would be less likely. This 157 
scenario would be relevant for de novo acquisition of low-fitness drug-resistant variants within an 158 
HIV-coinfected patient. Secondly, following the transmission of a drug-resistant strain with low 159 
fitness to a host with reduced immunity, weaker immune pressure acting on this strain might lead to 160 
better bacterial survival. The association between low-fitness rpoB variants and HIV coinfection 161 
remained significant even after adjusting for the different epidemiologic settings (i.e. countries) and 162 
the strain genetic background (i.e. Mtb lineages). We also observed that strains carrying the rpoB 163 
S450L resistance-conferring mutation were more likely to also carry a compensatory mutation in 164 
rpoA/C (97.4% vs. 2.6%, Table 1). Even though this phenomenon seems counter-intuitive, it has been 165 
described multiple times (7, 9, 34–36) and might thus point to different mechanisms of compensation 166 
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 7 
in strains carrying resistance mutations other than rpoB S450L. In addition, in our study, L4 strains 167 
were associated with low fitness rpoB variants, compared to L2 (Odds Ratio 3.10 [95% Confidence 168 
Interval 0.94, 10.21], p=0.06, Table 1), indicating that the strain genetic background could play a role 169 
in shaping the cost of resistance, as was previously shown for other bacterial species (37) and for 170 
other drugs (38). In the regression analysis, we had several categorical variables with only few 171 
observations. Therefore, statistical power especially for country of isolation was low and the results 172 
should be interpreted with care. 173 
HIV coinfected TB patients are generally thought of having a reduced potential for TB transmission 174 
(32, 39) because these patients have reduced formation of lung cavities, more extrapulmonary disease, 175 
and a shorter period of infectiousness due to earlier diagnosis or higher mortality, especially in the 176 
absence of anti-retroviral treatment and if antibiotic resistance is already present (4). Based on the 177 
over-representation of low-fitness rpoB mutations in the context of HIV coinfection, one would 178 
expect a further reduction of the transmission potential of drug-resistant TB in this context. Yet, 179 
outbreaks of drug-resistant TB in HIV coinfected patients have been reported (40). Such outbreaks 180 
might be explained by i) a higher risk of Mtb infection and reinfection due to diminished host 181 
immunity, ii) on-going transmission of drug-resistant Mtb from a larger pool of immune-competent 182 
TB patients to immune-compromised patients, iii) transmission occurring in conducive environments 183 
such as health care settings where both HIV coinfected individuals and DR-TB patients are more 184 
likely to co-exist, and iv) Mtb strains carrying high-fitness drug resistance mutations. 185 
In summary, using a global sample of drug-resistant Mtb clinical strains from HIV coinfected and 186 
HIV negative TB patients, we showed that low-fitness rpoB variants were overrepresented in HIV 187 
coinfected patients, and that this association was independent from other potential confounding 188 
factors. Taken together, our results provide new insights into how HIV coinfection can impact the 189 
fitness of drug-resistant Mtb. 190 
Data availability. The Mtb whole-genome sequences from the patients are available on NCBI under 191 
several project IDs. The accession number for each genome is indicated in the supplemental Table 1. 192 
 on A
ugust 4, 2020 at U
niversitaetsbibliothek B
ern
http://aac.asm
.org/
D
ow
nloaded from
 
 8 
Acknowledgments 193 
We thank all the sites that participated in this study and the patients whose data were used in this 194 
study. We thank Dr. Jan Hattendorf for providing statistical help and Dr. Sebastian M. Gygli for 195 
critically reading the manuscript. Calculations were performed at the sciCORE 196 
(http://scicore.unibas.ch/) scientific computing core facility at University of Basel. 197 
Funding 198 
This research was supported by the Swiss National Science Foundation (grant numbers 199 
153442, 310030_188888, 174281 and IZRJZ3_164171). The International Epidemiology Databases 200 
to Evaluate AIDS (IeDEA) is supported by the U.S. National Institutes of Health’s National Institute 201 
of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and 202 
Human Development, the National Cancer Institute, the National Institute of Mental Health, the 203 
National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute 204 
on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney 205 
Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific, 206 
U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, 207 
U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, 208 
U01AI069919. Informatics resources are supported by the Harmonist project, R24AI124872. This 209 
work is solely the responsibility of the authors and does not necessarily represent the official views of 210 
any of the institutions mentioned above. RJW is supported by Francis Crick Institute which receives 211 
funding from Wellcome (FC0010218), CRUK (FC0010218) and UKR1 (FC0010218). He is also 212 
supported by Wellcome (104803,203135). 213 
 214 
References 215 
 216 
1.  World Health Organization. 2019. Global Tuberculosis Report. 217 
2.  Getahun H, Gunneberg C, Granich R, Nunn P. 2010. HIV Infection–Associated Tuberculosis: 218 
The Epidemiology and the Response. Clin Infect Dis 50:S201–S207. 219 
3.  Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. 220 
 on A
ugust 4, 2020 at U
niversitaetsbibliothek B
ern
http://aac.asm
.org/
D
ow
nloaded from
 
 9 
2007. HIV Infection and Multidrug-Resistant Tuberculosis--The Perfect Storm. J Infect Dis 221 
196:S86-107. 222 
4.  Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, 223 
Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-224 
infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575–1580. 225 
5.  Eldholm V, Rieux A, Monteserin J, Lopez JM, Palmero D, Lopez B, Ritacco V, Didelot X, 226 
Balloux F. 2016. Impact of HIV co-infection on the evolution and transmission of multidrug-227 
resistant tuberculosis. Elife 5:1–19. 228 
6.  Cohen T, Murray M. 2004. Modeling epidemics of multidrug-resistant M. tuberculosis of 229 
heterogeneous fitness. Nat Med 10(10):1117–21. 230 
7.  Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, 231 
Gagneux S. 2012. Whole-genome sequencing of rifampicin-resistant Mycobacterium 232 
tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 233 
44:106–10. 234 
8.  Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, Harris SR, Bentley 235 
SD, Parkhill J, Nejentsev S, Hoffner SE, Horstmann RD, Brown T, Drobniewski F. 2012. 236 
Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res 22:735–45. 237 
9.  De Vos M, Müller B, Borrell S, Black PA, Van Helden PD, Warren RM, Gagneux S, Victor 238 
TC. 2013. Putative compensatory mutations in the rpoc gene of rifampin-resistant 239 
mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents 240 
Chemother 57:827–832. 241 
10.  Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Böttger EC. 2010. Directed 242 
mutagenesis of mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of 243 
aminoglycoside resistance in mycobacterium tuberculosis. Mol Microbiol 77:830–840. 244 
11.  Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM. 2006. The 245 
Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis. Science (80- ) 246 
312:1944–1946. 247 
12.  Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, Böttger EC. 248 
 on A
ugust 4, 2020 at U
niversitaetsbibliothek B
ern
http://aac.asm
.org/
D
ow
nloaded from
 
 10 
2002. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents 249 
Chemother 46:1204–1211. 250 
13.  Dye C, Williams BG, Espinal MA, Raviglione MC. 2002. Erasing the world’s slow stain: 251 
strategies to beat multidrug-resistant tuberculosis. Science (80- ) 295:2042–2046. 252 
14.  Cohen T, Dye C, Colijn C, Williams B, Murray M. 2009. Mathematical models of the 253 
epidemiology and control of drug-resistant TB. Expert Rev Respir Med 3:67–79. 254 
15.  Borrell S, Gagneux S. 2009. Infectiousness, reproductive fitness and evolution of drug-255 
resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 13:1456–1466. 256 
16.  Mesfin YM, Hailemariam D, Biadglign S, Kibret KT. 2014. Association between HIV/AIDS 257 
and multi-drug resistance tuberculosis: A systematic review and meta-analysis. PLoS One 9:1–258 
9. 259 
17.  Suchindran S, Brouwer ES, Van Rie A. 2009. Is HIV infection a risk factor for multi-drug 260 
resistant tuberculosis? A systematic review. PLoS One 4. 261 
18.  Khan PY, Yates TA, Osman M, Warren RM, van der Heijden Y, Padayatchi N, Nardell EA, 262 
Moore D, Mathema B, Gandhi N, Eldholm V, Dheda K, Hesseling AC, Mizrahi V, Rustomjee 263 
R, Pym A. 2019. Transmission of drug-resistant tuberculosis in HIV-endemic settings. Lancet 264 
Infect Dis 19:e77–e88. 265 
19.  Ssengooba W, Lukoye D, Meehan CJ, Kateete DP, Joloba ML, De Jong BC, Cobelens FG, 266 
Van Leth F. 2017. Tuberculosis resistance-conferring mutations with fitness cost among HIV-267 
positive individuals in Uganda. Int J Tuberc Lung Dis 21:531–536. 268 
20.  Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, Böttger EC. 269 
2002. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents 270 
Chemother 46:1204–1211. 271 
21.  Billington OJ, Mchugh TD, Gillespie SH. 1999. Physiological cost of rifampin resistance 272 
induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43:1866–273 
1869. 274 
22.  Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, Hartwell T, 275 
Graber C, Chi BH, Boulle A, Dabis F, Wools-Kaloustian K. 2012. Cohort profile: The 276 
 on A
ugust 4, 2020 at U
niversitaetsbibliothek B
ern
http://aac.asm
.org/
D
ow
nloaded from
 
 11 
international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J 277 
Epidemiol 41:1256–1264. 278 
23.  Mcgowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, Wolff M, Schechter M, Masys DR. 279 
2007. Cohort Profile: Caribbean, Central and South America Network for HIV research 280 
(CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate 281 
AIDS (IeDEA) programme. Int J Epidemiol 36:969–976. 282 
24.  Gagneux S, Burgos M V., DeRiemer K, Enciso A, Muñoz S, Hopewell PC, Small PM, Pym 283 
AS. 2006. Impact of bacterial genetics on the transmission of isoniazid-resistant 284 
Mycobacterium tuberculosis. PLoS Pathog 2:0603–0610. 285 
25.  Pym AS, Saint-Joanis B, Cole ST. 2002. Effect of katG mutations on the virulence of 286 
Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 287 
70:4955–4960. 288 
26.  Heym B, Alzari PM, Honore N, Cole ST. 1995. Missense mutations in the catalsase-289 
peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. 290 
Mol Microbiol 15:235–245. 291 
27.  van Soolingen D, de Haas PEW, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. 2000.  292 
Mutations at Amino Acid Position 315 of the katG Gene Are Associated with High‐Level 293 
Resistance to Isoniazid, Other Drug Resistance, and Successful Transmission of 294 
Mycobacterium tuberculosis in The Netherlands . J Infect Dis 182:1788–1790. 295 
28.  Billington OJ, McHugh TD, Gillespie SH. 1999. Physiological cost of rifampin resistance 296 
induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43:1866–9. 297 
29.  Mariam DH, Mengistu Y, Hoffner SE, Andersson DI. 2004. Effect of rpoB Mutations 298 
Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis. Antimicrob 299 
Agents Chemother 48:1289–1294. 300 
30.  Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. 301 
Tuberculosis drug resistance mutation database. PLoS Med 6:0132–0136. 302 
31.  Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, 303 
 on A
ugust 4, 2020 at U
niversitaetsbibliothek B
ern
http://aac.asm
.org/
D
ow
nloaded from
 
 12 
Diero L, Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AG, Collantes J, 304 
Avihingsanon A, Kawkitinarong K, Reinhard M, Hömke R, Huebner R, Gagneux S, Böttger 305 
EC, Egger M. 2019. Drug susceptibility testing and mortality in patients treated for 306 
tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis 19:298–307 
307. 308 
32.  Kwan C, Ernst JD. 2011. HIV and tuberculosis: A deadly human syndemic. Clin Microbiol 309 
Rev 24:351–376. 310 
33.  Hanrahan CF, Theron G, Bassett J, Dheda K, Scott L, Stevens W, Sanne I, Van Rie A. 2014. 311 
Xpert MTB/RIF as a measure of sputum bacillary burden: Variation by HIV status and 312 
immunosuppression. Am J Respir Crit Care Med 189:1426–1434. 313 
34.  Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, 314 
Bryant J, Parkhill J, Nejentsev S, Horstmann RD, Brown T, Drobniewski F. 2014. Evolution 315 
and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 46:279–316 
286. 317 
35.  Eldholm V, Monteserin J, Rieux A, Lopez B, Sobkowiak B, Ritacco V, Balloux F. 2015. Four 318 
decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain. 319 
Nat Commun 6:7119. 320 
36.  Song T, Park Y, Shamputa IC, Seo S, Lee SY, Jeon HS, Choi H, Lee M, Glynne RJ, Barnes 321 
SW, Walker JR, Batalov S, Yusim K, Feng S, Tung CS, Theiler J, Via LE, Boshoff HIM, 322 
Murakami KS, Korber B, Barry CE, Cho SN. 2014. Fitness costs of rifampicin resistance in 323 
Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and 324 
compensated by mutation in the β′ subunit of RNA polymerase. Mol Microbiol 91:1106–1119. 325 
37.  Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic resistance 326 
mutations and genetic background shape the  fitness effect of resistance across species of 327 
Pseudomonas. Proceedings Biol Sci 283. 328 
38.  Castro RAD, Ross A, Kamwela L, Reinhard M, Loiseau C, Feldmann J, Borrell S, Trauner A, 329 
Gagneux S. 2019. The Genetic Background Modulates the Evolution of Fluoroquinolone-330 
Resistance in Mycobacterium tuberculosis. Mol Biol Evol 37:195–207. 331 
 on A
ugust 4, 2020 at U
niversitaetsbibliothek B
ern
http://aac.asm
.org/
D
ow
nloaded from
 
 13 
39.  Huang CC, Tchetgen ET, Becerra MC, Cohen T, Hughes KC, Zhang Z, Calderon R, Yataco R, 332 
Contreras C, Galea J, Lecca L, Murray M. 2014. The effect of HIV-related 333 
immunosuppression on the risk of tuberculosis transmission to household contacts. Clin Infect 334 
Dis 58:765–774. 335 
40.  Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. 336 
2007. HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm. J Infect Dis 337 
196:S86–S107. 338 
 339 
List of Tables and figures 340 
 341 
Table 1. Results of the univariate and multivariate analysis showing host and bacterial factors 342 
associated with low fitness rpoB variants in 203 TB patients. 343 
 344 
Figure 1. A. Frequency of Mtb lineages by HIV status for countries sampled. Countries coloured 345 
in grey were sampled. The barplots indicate the proportion of each lineage represented in this study. 346 
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lineage 3 and red corresponds to Mtb lineage 4. Solid colour corresponds to HIV negative and hatches 348 
correspond to HIV coinfected TB patients. The number of genomes sampled in each country is 349 
indicated on top of the barplots. B. Phylogenetic tree of the dataset used in the study. Maximum 350 
likelihood phylogeny of 312 whole-genome sequences based on 18,531 variable positions. The scale 351 
bar indicates the number of substitutions per polymorphic site. The phylogeny was rooted on M. 352 
canettii. Mtb isolated from HIV coinfected patients are indicated by black dots. The peripheral ring 353 
depicts the country of isolation of the strains sequenced. 354 
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Table	1.	Results	of	the	univariate	and	multivariate	analysis	showing	host	and	bacterial	factors	associated	with	low	fitness	rpoB	variants	in	203	TB	patients.	
Dependent:  
fitness of rpoB variants 
 Low-
fitness 
High-
fitness 
univariable multivariable 
OR (95% CI) P OR (95% CI) P 
HIV status HIV- 71 (51.4) 67 (48.6) reference  reference  
0.003 
 
 HIV+ 47 (72.3) 18 (27.7) 2.46 (1.30-4.66) 0.006 4.58 (1.69-12.44) 
Presence of a compensatory 
mutation in rpoA/C 
No 117 (71.3) 47 (28.7) reference  reference  
 
< 0.0001  Yes 1 (2.6) 38 (97.4) 0.01 (0.00-0.08) < 0.0001 0.01 (0.00-0.06) 
        
Mtb lineage Lineage 2 16 (44.4) 20 (55.6) reference  reference  
 Lineage 4 99 (61.5) 62 (38.5) 2.00 (0.96-4.14) 0.06 3.10 (0.94-10.21) 0.06 
 Other (L1 or L3) 3 (50.0) 3 (50.0) 1.25 (0.22-7.05) 0.80 0.97 (0.11-8.31) 0.98 
 
Clustering of the genome No 109 (59.6) 74 (40.4) reference  reference  
0.94 
 
 Yes 9 (45.0) 11 (55.0) 0.56 (0.22-1.41) 0.21 1.05 (0.28-3.90) 
Country of isolation South Africa 29 (55.8) 23 (44.2) reference  reference  
 Democratic 
Republic of Congo 
11 (37.9) 18 (62.1) 0.48 (0.19-1.23) 0.13 0.39 (0.12-1.34) 0.14 
 Côte d’Ivoire 35 (79.5) 9 (20.5) 3.08 (1.24-7.70) 0.02 2.04 (0.58-7.23) 0.27 
 Kenya 4 (66.7) 2 (33.3) 1.59 (0.27-9.44) 0.61 0.94 (0.10-8.42) 0.96 
 Nigeria 20 (58.8) 14 (41.2) 1.13 (0.47-2.72) 0.78 1.00 (0.29-3.40) 0.99 
 Peru 16 (53.3) 14 (46.7) 0.91 (0.37-2.23) 0.83 1.49 (0.33-6.70) 0.60 
 Thailand 3 (37.5) 5 (62.5) 0.48 (0.10-2.20) 0.34 0.42 (0.07-2.65) 0.36 
 
Age Mean (SD) 32.5 (10.4) 34.3 (12.3) 0.99 (0.96-1.01) 0.25 0.97 (0.94-1.01) 0.10 
 
Sex  Female 47 (59.5) 32 (40.5) reference  
0.75 
  
0.52 
 
 Male 71 (57.3) 53 (42.7) 0.91 (0.51-1.62) 0.77 (0.34-1.71) 
History of TB disease No 35 (52.2) 32 (47.8) reference  
0.23 
  
0.94  Yes 83 (61.0) 53 (39.0) 1.43 (0.79-2.58) 0.96 (0.34-2.73) 
Number	of	observations	in	model	=	203;	CI	=	confidence	interval;	The	odds	ratio	and	p-value	are	obtained	from	the	regression	model.	
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